Piper Jaffary "NEAR TERM for SRPT $60-$80 AFTER APPROVAL $160 " **link**
Sarepta Therapeutics (SRPT) Jumps on Bullish CommentS
November 21, 2012 9:18 AM EST
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) is seeing strong pre-open action following positive comments from analysts at Piper Jaffray. The firm said it has the potential to be a $160/share stock but a nearer-term range could be $60-$80/share.
Wednesday's Bio-Pharma Catalyst Trades And Watch List
November 21, 2012
I think it's a good bet Sarepta gets the early approval, which would likely cause the stock price to explode from its current price level of $27 a share -- I can easily see a stock price approaching $75 or higher here.
DMD is a very rare disease that affects mainly children -- a potential cure for any form of MD would be on par with Jonas Salk's discovery of the Polio vaccine in my strong opinion.